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Abstract
Background: Cancer staging and treatment presumes a division into localized or metastatic disease. We proposed an
intermediate state defined by #5 cumulative metastasis(es), termed oligometastases. In contrast to widespread
polymetastases, oligometastatic patients may benefit from metastasis-directed local treatments. However, many patients
who initially present with oligometastases progress to polymetastases. Predictors of progression could improve patient
selection for metastasis-directed therapy.
Methods: Here, we identified patterns of microRNA expression of tumor samples from oligometastatic patients treated with
high-dose radiotherapy.
Results: Patients who failed to develop polymetastases are characterized by unique prioritized features of a microRNA
classifier that includes the microRNA-200 family. We created an oligometastatic-polymetastatic xenograft model in which
the patient-derived microRNAs discriminated between the two metastatic outcomes. MicroRNA-200c enhancement in an
oligometastatic cell line resulted in polymetastatic progression.
Conclusions: These results demonstrate a biological basis for oligometastases and a potential for using microRNA
expression to identify patients most likely to remain oligometastatic after metastasis-directed treatment.
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Introduction
Metastases are the leading cause of cancer death. Standard
therapies for most metastatic cancers are systemic chemotherapy,
hormonal manipulation or newer targeted therapies. However,
these agents are rarely curative. We proposed that during the
evolution of some tumors, an intermediate metastatic state exists
called oligometastasis(es). We hypothesized that these patients,
exhibiting a less aggressive biology with limited [1,2,3] cumulative
metastasis(es) in less than 4 months from time of first metastatic
progression, could potentially benefit from metastasis-directed
therapy [1,3]. This hypothesis was based on long-term survival
following surgical resection of limited lung [2], liver [4,5], or
adrenal metastases[6] from a variety of primary sites. An
oligometastatic state is a common clinical presentation although
it has only recently received attention as a defined subset of
metastasis [1,7,8]. Employing radiotherapy improvements, termed
hypofractionated image-guided radiotherapy (HIGRT) or stereo-
tactic body radiotherapy (SBRT), we [9] and others [8] treated
metastatic lesions using a few high-doses of radiotherapy in
inoperable patients with #5 metastasis(es). Initial reports demon-
strated long-term disease free survival in some treated patients
[8,9,10,11]. However, many oligometastatic patients developed
widespread cancer progression and were subsequently classified as
polymetastatic (.5 new metastatic sites, see methods). We
hypothesized that molecular markers could be developed for
identifying patients who would fail to become polymetastatic. We
analyzed microRNA expression derived from paraffin blocks of
patients who were oligometastatic at time of treatment with
curative intent radiotherapy. We report unique prioritized features
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28650of a potential microRNA classifier associated with persistence in
an oligometastatic state [1,3]. We also confirmed that microRNA-
200c, a top prioritized microRNA elevated in clinical polymetas-
tases, regulates the conversion from oligo- to poly- metastasis(es) in
an oligometastatic mouse model.
Materials and Methods
Patient population and clinical data
All human studies were carried out according to protocols
approved by the Institutional Review Board (IRB) at the
University of Chicago. Written consent forms were obtained from
all participants involved in the study. Patients had 1–5 metastatic
tumors that could be treated with hypofractionated radiation and
encompassed in a conformal radiation field without undue
expected toxicity based on size (,10 cm) or location. Patients
underwent computed tomography based radiation treatment
planning accounting for respiratory induced tumor motion and
aided by intravenous and oral contrast media as needed. The
attending radiation oncologist contoured tumors with no margin
for microscopic extension using all available clinical, radiographic,
and metabolic data then expanded 5–10 mm to account for set-up
error. A variety of non-overlapping axial fields and non-coplanar
fields were combined to achieve the optimal radiation distribution
to tumors while minimizing radiation to surrounding non-involved
organs. The estimated normal tissue tolerances from the available
literature were referenced in determining radiation plans
[8,9,12,13]. Typically, radiation was delivered in three doses (8–
16 Gy per dose) for those treated on protocol and in a ten-dose
regimen (50 Gy total dose, 5 Gy per dose) for those treated off
protocol. Furthermore, prospective level-1 evidence has demon-
strated this approach, with or without whole brain radiotherapy
(WBRT) [14], leads to 80–90% local control of lesions. From
December 2004 to June 2010, 34 patients were treated with
HIGRT at all sites of active limited metastatic disease [9] (Tables
S1, S2). Eleven of these patients were analyzed retrospectively,
while 23 patients were included prospectively from a previously
reported radiotherapy protocol for oligometastasis(es) [9]. For
inclusion in this report, availability of at least one formalin fixed
paraffin embedded (FFPE) tissue biopsy from the primary site or a
metastatic site was also required. Patients with small volume
biopsies or fine needle aspirations were excluded, as there was not
enough tissue for RNA extraction.
We collected paired primary and metastatic tumor samples
from 5 patients, primary tumors only from 20 patients, and
metastatic tumors only from 9 patients. Following radiotherapy,
patients underwent physical examination and imaging (whole
body CT and/or FDG/PET or MRI) at one month following
HIGRT to assess initial response and then every three months
subsequently for up to 41 months. Metastasis(es) were defined
based on axial imaging using CT scans of the Chest/Abdomen/
Pelvis with iodinated contrast. For brain imaging, gadolinium
enhanced MRI scans was used. The modality chosen for follow-up
was based on the imaging employed to initially evaluate and treat
the patient’’. The percentage of imaging modalities used to select
and treat patients is included in Table S5c. Survival was defined
as the time from the initiation of radiation treatment until death
from any cause. Patients were classified into two groups based on
response after completion of radiation therapy: polymetastatic patients
had (i) progression in developing more than 5 new tumors in less
than 4 months from time of first metastatic progression, or (ii)
progression within a body cavity that by definition would imply
the presence of diffuse metastatic disease (i.e. pericardial, pleural,
cerebrospinal, or ascitic fluid). In contrast, Oligometastatic (Oligo)
patients had either no evidence of progression (including 10
patients) or insufficient rate of metastatic progression to satisfy
the above criteria for polymetastases.
Human tissue acquisition, RNA extraction and microRNA
profiling
After Institutional Review Board approval, FFPE primary and
metastatic tissue samples were received in triplicate from the
Department of Pathology at the University of Chicago. Total
RNA was extracted from FFPE tissue samples using RecoverAll
Total Nucleic Acid Isolation Kit (Applied Biosystems, Allston,
MA, USA). Tissues of #80 mm were sectioned into sizes of 5–
20 mm and underwent deparaffinization, protease digestion,
nucleic acid isolation, and nuclease digestion/purification accord-
ing to the manufacturer’s protocol for RNA isolation. Sample
concentrations were determined using the Qubit Quantification
Platform (Invitrogen, Carlsbad, CA, USA) and normalized to
10 ng/mL.
Ten mL of each triplicate were combined and 3 mL of this
pooled sample were used to obtain a total of 30 ng of total RNA.
Single stranded cDNA synthesis and pre-amplification were
performed according to the manufacturer’s protocols (Applied
Biosystems, Allston, MA, USA). Real-time qPCR of 376 distinct
microRNAs was performed using human Taqman MicroRNA
Array A Card v2.0 (Applied Biosystems, Allston, MA) according to
the manufacturer’s protocol.
Differential microRNA expression for prioritization of
oligo vs polymetastases from TaqMan Arrays
Among the 42 tumor samples included in the study, five patients
had paired metastatic and primary tumor samples, while the
remaining samples were from distinct patients with either primary
or metastatic tumor tissue analyzed. In addition, 2 patients
contributed samples from two distinct metastatic sites (Tables S1,
S2). The raw Ct (threshold cycle) values and array qualities were
analyzed and normalized using HTqPCR package in Bioconduc-
tor (Methods S1). Forty-two of the forty-five human samples
assayed by TaqMan microRNA Card A for having more than 200
detectable microRNAs (Ct,38) were included in the analysis,
while 3 samples with less than 120 detectable microRNAs were
excluded (Figure S3). For the remaining 42 samples, quantile
normalization was performed to control for potential genome-wide
tissue/samples-specific bias. The coefficient of variation (CV) of
external and endogenous controls was #5% after normalization.
The raw Ct values normalized with the pooled controls of RNU-
44 and RNU-48 were used to evaluate the impact of different
normalization on our results. RNU-44 and RNU-88 are two small
non-coding RNA (ncRNAs) that are expressed both abundantly
and stably. They are widely used as endogenous control for
microRNA expression profiling. Quantile normalization was
applied to the datasets using default parameters of the R/
Bioconductor package HTqPCR [15]. The raw and normalized
TaqMan array data of these clinical samples have been deposited
in the NCBI GEO database with accession number GSE25552.
Unsupervised hierarchical clustering was conducted using
dChip software with the default parameters (‘‘average’’ linkage
and ‘‘1-Pearson’’ distance metric) [16]. The microRNA’s expres-
sion profiles included in the unsupervised hierarchical clustering
analyses had a standard deviation .0.5 across all samples
regardless of the oligo- or polymetastastic status, resulting in the
detection of 344, 335 and 330 out of 384 microRNA probes in
primary only, metastatic only, and paired primary-metastatic
datasets, respectively. This unbiased procedure removed uninfor-
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statistical significance after adjustment for multiple comparisons,
thus deregulated microRNA expression of oligo- vs polymetastases
groups in the metastatic samples and in the primary samples were
‘‘prioritized’’ using a two-tailed Student t-test at an unadjusted p-
value ,0.05 and organized according to their fold change. The
prioritized microRNAs from primary sample, Pr-miRs, were used
to predict the oligo- vs poly- metastatic progression in the
metastatic samples using the default parameters and unsupervised
Principal Component Analysis (PCA) of the R package ‘‘ade4’’
[17,18]. Similarly, the prioritized microRNAs from the metasta-
static tissue sample, M-miRs, were used to predict the oligo- vs
poly- metastatic progression in the primary samples datasets. For
permutation resampling of the samples, see Methods S1.
Validation of prioritized oligo vs polymetastases
microRNA signatures using independent datasets and
ROC curves
MicroRNAs prioritized from primary tumors (Pr-miRs) and
those prioritized from metastatic tumors (M-miRs) lists were used
as features to compute the first component in these independent
validation sets of microRNAs (Flow diagram of samples in Figure
S4). The clinical definitions of oligo- and polymetastatic
progression are summarized in Figure S5. PCA and 1
st
component were calculated in the validation sets using the Pr-
miRs and M-miRs microRNA lists. The computed first compo-
nent was then used to generate an ROC (Receiver Operating
Characteristic) curve using R ‘‘caTools’’ package of Bioconductor
[16,19] for the validation in human samples. The ROC curve
plots the true positive rate against the false positive rate according
to different possible thresholds for oligo vs polymetastases
determination. An empirical p-value was calculated for the area
under the curve (AUC) of the ROC by permutation resampling. In
each permutation, class assignment of oligo or polymetastases was
sampled without replacement in the validation sets. This
simulation was performed 1000 times for metastatic tumor
samples using Pr-miRs and likewise for primary tumor samples
using M-miRs. We thus generated a conservative empirical
distribution of AUCs for separating oligometastatic samples from
polymetastatic samples using the 17 Pr-miRs and the 29 M-miRs,
respectively. Scatter plots and non parametric Mann-Whitney tests
were performed using GraphPad Prism version 4.03.
Cell Cultures
Parental MDA-MB-435-GFP cell line was derived from the
MDA-MB-435S (HTB-129) originally obtained from American
Type Culture Collection (ATCC, Manassas, VA, USA). MDA-
MB-435-GFP cell line authentication was performed by Fragment
Analysis Facility, Johns Hopkins University (Baltimore, MD, USA)
using Identifier AB Applied Biosystems. The STR profile perfectly
matches that of MDA-MB-435S (HTB-129) in the ATCC
database and there is no evidence of contamination with other
cell types. MDA-MB-435-GFP cell line stably expressing green
fluorescent protein (GFP) was generated by Dr. Robert Hoffman
(AntiCancer Inc.) as previously described [20]. We have been
using this model routinely to produce experimental lung
metastasis(es) for conducting in vivo imaging experiments [21]
(data not shown). Cells were maintained in DMEM high glucose
supplemented with 10% FBS+200 mg/ml G418 (Gibco). B16F1
murine melanoma cell lines were obtained from ATCC (Manas-
sas, VA, USA) and cultured in RPMI 1640 media (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA, USA). Cells were sub-
cultured for at least three passages before harvesting at their linear
growth phase (approximately 70–80% confluent) for tail vein
tumor injection.
Generation of derivative MDA-MB-435 lung
oligometastatic (L1-R1) or polymetastatic (L1Mic-R1) cell
lines from in vivo modeling of experimental lung
colonization assays
All animal studies were carried out according to protocols
approved by the IACUC Committee at the University of Chicago
(Protocol ID#71685). The tail vein experimental lung coloniza-
tion assay was performed to model the development of MDA-MB-
435-GFP oligometastatic or polymetastatic phenotype in the lung
and other organs in vivo. Animal work was conducted in
accordance with an approved protocol. Age and weight-matched
NCI athymic female mice were used, and 2610
6 viable cells were
injected into the lateral tail vein. Animals were sacrificed once
visible macroscopic metastatic lesions were identified upon
external examination using Sellstrom Z87 fluorescence goggles
and LDP 470 nm bright blue flashlight. Otherwise, metastatic
colonization of recipient mouse lung and other organs by MDA-
MB-435-GFP cells was determined and scored at 12 weeks post
tumor cell injection, the experimental end-point.
To generate MDA-MB-435-GFP lung derivative cell lines that
would produce oligo- and polymetastatic dissemination upon tail
vein injection of the tumor cells, we first generated paired cell
lines derived from the same lung tissue that were obtained from
lung macrometastases (L1-R1) and from live tumor cells that
resided in the macrometastasis-free component of the lung in the
same animal (L1Mic-R1). Subsequently, we characterized the
oligo- and polymetastatic potential of L1-R1 and L1Mic-R1 lung
cell lines using the experimental lung metastasis assay (n=15 per
line). We then established derivative MDA-MB-435-GFP cell
lines from distinct lungs of oligo- and poly-metastatic animals
that received the injection of L1-R1 cells and L1Mic-R1-435-
GFP cells, respectively. Tumor cells were purified via G418
antibiotic selection for GFP expression. All three distinct L1-R2-
lung cell lines that we obtained and four of the six distinct
L1Mic-R2-435-GFP cell lines were used for microRNA profiling
(see below). We also conducted an additional round of lung
experimental metastasis assays (n=6 for each cell line, 4 cell
lines for each phenotype) to confirm the stability of phenotypic
separation of the three L1-R2 and four L1Mic-R2 cell lines we
profiled.
Quantitative RT-PCR analysis of microRNA expression of
the L1-R2- and L1Mic-R2-435-GFP cell lines
Total RNA from three oligometastatic L1-R2- and four
polymetastatic L1Mic-R2-435-GFP lung derivative cell lines was
extracted and purified using TRIzol (Invitrogen, Carlsbad, CA,
USA) according to manufacturer’s instructions. Genome wide
microRNA expression changes of 367 distinct mature human
microRNAs between oligo and polymetastases cell lines was
measured using TaqMan Human MicroRNA Array A card v2.0
(Applied Biosystems, Allston, MA, USA) according to the
manufacturer’s instructions. Raw data was imported and
normalized using SDS RQ Manager software (Applied Biosys-
tems, Allston, MA, USA). In our analysis, the baseline Ct was
automatically set and we used a threshold of 0.3 for TaqMan
raw data normalization. The raw and quantile normalized
TaqMan array data of these clinical samples have been
deposited in the NCBI GEO database with accession number
GSE29890.
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miRIDIAN mimics treatment on metastatic progression in
two mouse models
40% confluent L1-R2-435-GFP cells or B16F1 cells were
transfected with 100 nM Control mimics (Cat#110CN-001000-
01), or species-specific miR-200c miRIDIAN mimics (L1-R2-435-
GFP: #C-300646-05-0010; B16F1: # MIMAT0000039) (Dhar-
macon, Lafeyette, CO, USA) using Oligofectamine (Invitrogen,
Carlsbad, CA, USA) as we previously described [22]. Transfection
efficiency was optimized and estimated to be .90%. In vivo tail-
vein injection of control or specific mimics-treated L1-R2-GFP
(2610
6 cells/mouse) or B16F1 cells (1610
5 cells/mouse) was
performed at 48 h after transfection.
For the L1-R2-435-GFP model, tumor-cell inoculated mice
were monitored and scored for tumor metastasis development and
progression as described above. For the B16F1 mouse melanoma
model, 4–6 weeks C57BL/6 female mice were obtained from
Harlan labs (Indianapolis, IN, USA). The care and treatment of
experimental animals was in accordance with institutional
guidelines at the University of Chicago. Mice were sacrificed 14
days after tail vein injections. The thoracic cavity of each mouse
was opened and lungs were removed in their entirety and surface
lung metastasis(es) were scored using methods previously described
[23].
After being excised from each mouse, the lung tissue was fixed
in 10% formalin, embedded in paraffin, cut into 5 micrometers
sections, stained with hematoxylin and eosin and examined for
macro- or micrometastases. 5 mice were examined from each
group.
TaqMan quantification of putative microRNA-200c gene
targets expression
L1-R2-435-GFP cells were treated with equal amount of
control-mimics or microRNA-200c mimics for 48 hours as
described above. Thereafter, one fifth of the transfected cells were
used for total RNA extraction and the rest were used for tail-vein
injection. The expression of Zeb1 (Hs00232783_m1), Zeb2
(Hs00207691_m1), NEDD4 (Hs00406454_m1) and FGD1
(Hs00171676_m1) was determined by TaqMan RT-PCR assay
according to manufacturer’s instructions. GAPDH (4326317E)
expression was used as normalization control.
Results
To identify molecular changes associated with oligo or
polymetastatic progression we extracted RNA from 42 paraffin
embedded samples of primary and metastatic tumors of patients
treated with stereotactic radiotherapy (see Tables S1, S2 for
patient characteristics) and profiled the resultant microRNAs using
TaqMan Human MicroRNA Array A card v2.0 (see Methods).
Among the 42 tumor samples included in the study, five patients
had paired metastatic and primary tumor samples, while the
remaining samples were from distinct patients with either primary
or metastatic tumor tissue analyzed. In addition, 2 patients
contributed samples from two distinct metastatic sites (Tables S1,
S2). No differences were observed in pre-radiotherapy clinical
variables (Tables S3a–b) or histopathology between patients who
remained oligometastatic and those who progressed to a
polymetastatic state (logit regression, data not shown). Median
Figure 1. Unsupervised hierarchical clustering of: (a) metastatic
tumors microRNA expression showing clustering of oligo- vs polymeta-
static samples. Red, black and green represent TaqMan qPCR Ct values
above, at or below mean level, respectively, across all samples and 335
microRNAs. As shown, all seven polymetastatic samples are clustered
together, while eight out of ten oligometastatic samples cluster
together. This suggests that the oligo vs polymetastatic phenotype is
overriding other predictable groupings such as histology of primary
tumor and metastatic site. However, in the primary samples, the
primary site was the dominant signal of the unsupervised hierarchical
clustering (Fig. S1). (b) MicroRNA expression of five patients with
paired primary and metastatic samples showing clustering of (i) primary
(Pr) and metastasis(es) sample sites of the same patient and (ii) oligo
(Ol-) vs polymetastatic (Pol-) progression phenotype across patients.
doi:10.1371/journal.pone.0028650.g001
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oligometastatic (Tables S3, S4, S5).
Unsupervised hierarchical clustering of patients with metastatic
tumor samples profiled correctly classified the clinical course of 8
of 10 (80%) samples from patients who remained oligometastatic
and 6 of 6 (100%) samples from patients who eventually
progressed to widespread, polymetastases (Fig. 1a, P=0.007,
two-tailed Fisher Exact Test). These data demonstrate that
detected patterns of microRNA expression from metastatic
samples are dominated by oligometastatic or polymetastatic
progression of disease (Fig. 1, Table S1). In contrast, unsuper-
vised hierarchical clustering using microRNA expression of tissue
exclusively obtained from primary tumors of patients failed to
accurately separate oligometastatic and polymetastatic patients
(Fig. S1). Indeed, unsupervised methods are not designed to
identify a phenotype, such as the subtle distinction between oligo-
and poly-metastases, while the primary tumor cells are more
heterogeneous than those of metastases. We thus obtained
microRNA profiles of 5 patients for whom both primary and
metastatic samples were collected. In four of five patients primary
and metastatic tumor samples, the microRNA of the same patient
clustered together consistent with other reports. Furthermore, in
this paired sample analysis, the separation of oligometastatic vs.
polymetastatic progression was confirmed both across different
patients (Fig. 1b).
To derive microRNA expression patterns associated with
patients remaining oligometastatic versus progressing to poly-
metastases, we compared expression of individual microRNAs
between the oligometastatic and polymetastatic groups in the
metastatic tumor dataset and the primary tumor set independently
using a two-tailed Student t-test (P,0.05). We prioritized 29 and
17 microRNAs that characterized oligometastatic or polymeta-
static progression in the two datasets, respectively (Table 1,
Fig. 1, Figure S1). We designated these sets as 29 M-miRs
(microRNAs prioritized from metastatic tumors, Table 1a) and
17 Pr-miRs (microRNAs prioritized from primary tumors,
Table 1b). To validate Pr-miR and M-miR, we applied them
to patients in the alternative dataset (ie Pr-miR was tested in the
patients with metastatic tissue obtained and M-miR in the patients
with primary tissue profiled). This analysis was performed using
the unsupervised first component of a principal component
analysis (PCA) (Methods, Methods S1). At different cutoff
Table 1. a and b. Prioritized microRNAs by Expression Analysis of Oligo- vs Polymetastases in Human Metastatic and Primary
Tumors.
Table 1a. Oligo vs polymetastases progression in metastatic tumor samples (M-miRs)
MicroRNA FC p (t-test) MicroRNA FC p (t-test)
miR-654-3p 28.3 0.028 miR-95 2.4 0.029
miR-654-5p 24.6 0.041 miR-500 22.1 0.047
miR-200c 20.1 0.029 miR-328 22.2 0.002
miR-105 15.9 0.023 miR-125a-3p 22.2 0.048
miR-375 14.9 0.027 miR-140-5p 22.2 0.024
miR-135b 7.8 0.013 miR-29c 22.4 0.008
miR-200b 5.7 0.032 miR-140-3p 22.4 0.018
miR-410 5.4 0.01 miR-489 22.7 0.008
miR-376a 4.7 0.049 miR-331-5p 23.6 0.046
miR-323-3p 4.1 0.023 miR-193a-3p 26.7 0.036
miR-539 4 0.045 miR-199b-5p 29.5 0.043
miR-642 3.6 0.024 miR-502-5p 218.3 0.034
miR-370 3.2 0.031 miR-545 220.2 0.022
miR-127-3p 3 0.04 miR-363 221.6 0.012
miR-212 2.7 0.002
Table 1b. Oligo vs polymetastases progression in primary tumor samples (Pr-miRs)
MicroRNA FC p (t-test) MicroRNA FC p (t-test)
miR-654-3p 17 0.018 miR-127-3p 1.7 0.036
miR-542-3p 14.3 0.014 miR-24 21.5 0.014
miR-548c-3p 10 0.001 miR-27b 21.6 0.025
miR-758 8.8 0.045 miR-197 21.9 0.032
miR-483-5p 3.6 0.038 miR-330-3p 22 0.01
miR-369-3p 3.6 0.047 miR-671-3p 22.2 0.012
miR-134 2.5 0.023 miR-23b 22.8 0.048
miR-337-5p 2.3 0.027 miR-301b 216.8 0.007
miR-181a 2 0.034
Prioritized microRNAs by comparing their expression in oligo- and polymetastatic groups using Student t-test (unadjusted p,5%). A positive fold change (FC) represent
elevated expression in polymetastatic progression as compared to oligometastasis(es).
doi:10.1371/journal.pone.0028650.t001
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combinations of sensitivities and specificities reflect their ability to
discriminate between the oligo- vs polymetastatic tissue samples
thus are plotted as receiver operating characteristic (ROC) curves
in Fig. 2. The resulting prioritized microRNAs from primary
samples, Pr-miRs, demonstrate good discrimination between
remaining oligometastatic and developing widespread polymetas-
tases in the metastatic sample set (Fig. 2a, AUC=0.85; empirical
P=0.015 by permutation resampling). Similarly, M-miRs applied
to the group of primary tumors discriminated between the two
phenotypes in primary tumors (Fig. 2b; AUC=0.74, empirical
P=0.055).
Since differentially expressed microRNA profiles were generat-
ed from a relatively small patient cohort, we developed a stable
human tumor (MDA-MB-435-GFP) xenograft model of oligome-
tastatic and polymetastatic progression by conducting three
consecutive rounds of experimental lung colonization assays (see
Methods). In the first round, we generated paired oligometas-
tases-like lung derivative L1-R1-435-GFP (L1-R1) or polymetas-
tases-like L1Mic-R1-435-GFP (L1Mic-R1) cell lines. When tested
in vivo, these cells stably recapitulated human oligometastatic (#5
total metastasis(es) in mouse) and polymetastatic (.5 metastases in
mouse) states at week 12 in subsequent testing (Fig. 3a–e, Fig.
S2, see Methods). For example, in the second round (fifteen mice
for each cell line), L1Mic-R1 cells produced widespread
polymetastases in the lung and other organs at a higher incidence
and had significantly faster time kinetics of metastatic dissemina-
tion than the oligo-like L1-R1 cell line (odds ratio of poly=10 at
week 12: P=0.0092, two-tailed Fisher’s exact test; time kinetics at
week 9: P=5610
25, two-tailed FET; Fig. 3e). We subsequently
generated three oligometastatic L1-R2-435-GFP (L1-R2) lung cell
lines as well as four polymetastatic L1Mic-R2-435-GFP (L1Mic-
R2) lung cell lines from seven distinct animals of the second in vivo
passage for further biological characterization and for microRNA
expression analysis (see Methods, Fig. 3e, Fig. S2). PCA using
the first component shows that the prioritized Pr-miRs and M-
miRs (Table 1a–b) accurately split the MDA-MB-435 lung
derivative cell lines into oligometastatic L1-R2 and polymetastatic
L1Mic-R2 groups. These observations have provided further
evidence that distinct microRNA expression patterns derived from
patients underlie the molecular differences between the stable
oligometastatic phenotype and that of polymetastatic progression
(Fig. 4a–b).
Next, we investigated whether specific microRNAs differentially
expressed between oligometastatic and polymetastatic patients
were associated with phenotypic change from oligo- to poly-
metastases. Since metastatic development is a multi-step process
and all patients by definition had 1–5 metastasis(es) at time of
radiation treatment, we hypothesized that late events in the
metastatic process were likely to account for differences in the
oligo- and polymetastastic phenotypes. Primary tumors are likely
more heterogeneous with respect to cells with metastatic potential
[24], thus we focused on the prioritized microRNAs derived from
the metastatic tissue samples. We rank ordered the 29 prioritized
microRNAs obtained from metastatic tissue according to fold
change. As shown in Table 1b, the two microRNAs with highest
fold changes, miR-654-3p and miR-654-5p, are produced in the
cells by two-complementary/opposite strands of the same
precursor microRNAs. Their joint expression suggests a common
transcriptional event likely unrelated to their specific function.
Figure 2. Validation of microRNA expression signatures in
human datasets: prediction of oligometastatic progression by
microRNA expression signatures. The Receiver Operating Charac-
teristic (ROC) curves describe how accurately the prioritized microRNAs
can discriminate between oligo- vs poly- metastasis(es) samples by
plotting the possible combinations of sensitivity and specificity
obtained at different cutoff points of the prioritized microRNA classifier.
(a) Pr-miRs, 17 prioritized microRNAs from the primary tumors sample
(Table 1b), were used to predict oligometastasis(es) progression in the
16 metastatic tumor samples using permutation controlled ROC curves
of the first PCA component (See Methods). (b) Similarly, M-miRs, 29
prioritized microRNAs from the metastatic tumor samples (Table 1a),
were used to predict oligometastasis(es) progression in the 26 primary
samples. Empirical P values of the AUC were calculated from empirical
permutation resampling (see Methods S1).
doi:10.1371/journal.pone.0028650.g002
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investigated the microRNA with the next highest fold change,
microRNA-200c (Table 1a, FC=20.1, p=0.029), as proof of
principle that these microRNAs mediate the oligo- to polymeta-
static progression. MicroRNA-200c, along with other members of
the microRNA-200 family including microRNA-200b, (Table 1a,
FC=5.7, P=0.032) has been widely reported to be involved in
metastasis [25,26,27]. MicroRNA-200c has anti- or pro-metastatic
functions depending on at which point in the metastatic cascade it
acts. For example, it inhibits the invasiveness of cancer cells at the
primary site by suppressing epithelial to mesenchymal transition
(EMT) [28], while it enhances colonization efficiency at distant
metastatic sites by promoting the reversion from EMT to
mesenchymal-to-epithelial-transition [27,29].
Figure 3. Histological and in vivo characterization of oligo- and poly- metastasis(es) derived from tail-vein injected MDA-MB-435-
GFP lung derivative cell lines. 2610
6 purified MDA-MB-435-GFP lung derivative cell lines established from lungs harboring oligo- (L1-R1) or poly-
(L1Mic-R1) metastases respectively were injected via tail-vein. Animals developing macroscopic observable metastases were sacrificed at the timeo f
this finding. The rest of the animals were sacrificed at 12-weeks post tumor cell injection. Necropsy was performed to score macroscopic metastatic
lesions and lungs were harvested and paraffin embedded for histological characterization. (a) Representative lung metastatic-foci developed from
oligmetastatic L1-R1 cell line harvested at week-12 or (b) a polymetastatic L1Mic-R1 cell line, harvested at week-7 shown by H&E staining (arrows,
406magnification). (c) An enlargement (2006) of the insert in (b). (d) Representative fluorescent in vivo imaging identifying extensive lung and
whole body polymetastatic lesions after tail vein injection with L1Mic-R1 cells (OV-100 imager, green fluorescence=metastatic lesions). (e) Oligo- vs
polymetastases progression in these 29 NCI athymic female mice establish that polymetastatic L1Mic-R1 cells produced more aggressive metastatic
progression than the oligometastatic L1-R1 cells (odds ratio at week 12=10; P=0.0092; two-tailed Fischer Exact Test). Additionally, L1Mic-R1
produced more aggressive metastatic progression: at week 9, 73% of L1Mic-R1 had developed polymetastases as compared to none among those
exposed to L1-R1 (P=5610
25; two-tailed Fischer Exact Test).
doi:10.1371/journal.pone.0028650.g003
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28650To demonstrate prioritized microRNAs from the clinical
samples are functionally important, as a proof of principle, we
examined whether microRNA-200c may regulate oligo- to
polymetastatic progression. We specifically enhanced the function
of this microRNA via synthetic mimics (see Methods) in the
most stable oligo-like L1-R2 cell line prior to tail vein injection.
Whereas injection of non-treated or control mimics-treated L1-R2
cells produced predominantly oligometastases or no macroscopic
metastasis(es) (Fig. 5a, Oligo: non-treated=2, control mimics=2;
no metastasis(es): non-treated=3, control mimics=5; poly=0),
increased expression of microRNA-200c in the L1-R2 cell line
produced significantly more mice with polymetastases (Fig. 5a,
oligo=2; no metastasis(es)=2; poly=5; P=0.012, one-tailed
Mann Whitney U, for polymetastases compared to controls).
Real-time imaging visualization and histological characterization
also confirmed this conversion (Fig. 5b–c).
Since microRNA-200c has mainly been characterized as a
metastasis suppressor, our prediction of its role in promoting oligo-
to polymetastatic progression is novel. To further examine the pro-
metastasis role of microRNA-200c, we also enhanced its function
in the melanoma cell line B16F1 that has low metastatic
propensity. Similar to our observations in the L1-R2-435-GFP
xenograft model, treatment of B16F1 cells with microRNA-200c
mimics resulted in significantly more macroscopic lung metastases
than the control mimics-treated cells in a syngeneic mouse model.
The average number of surface lung metastases per mouse was 2.8
versus 20.3 at 2 weeks (P=0.0057, one-tailed Mann Whitney U
Test) for controls and microRNA-200c mimics respectively
(Fig. 5d–e). These results demonstrate significant increases in
lung colonization efficiency due to enhancement of microRNA-
200c function (Fig. 5d).
To determine the specificity of microRNA-200c in mediating
the observed phenotype switch, we examined messenger RNA
(mRNA) expression of Zeb1 and Zeb2 by Taqman RT-PCR in
tail vein injected L2-R2 cells that were treated with microRNA-
200c mimics. These two genes are validated microRNA 200c
targets [26,30]. In microRNA-200c mimics treated L1-R2 cells,
the expression Zeb1 and Zeb2 was decreased by 53% and 23%,
respectively compared to the control mimics-treated cells (Fig. 6a)
confirming target specificity. Since one mechanism by which ZEB
promotes EMT state is through transcriptional suppression of E-
cadherin expression [25,26,31], and L1-R2-435-GFP cell lines
were negative for E-cadherin [Fig. 6b(i)] and positive for
vimentin [Fig. 6b(ii)], we searched for additional putative
microRNA-200c gene targets that are validated regulators of
EMT or metastasis.
We computationally prioritized putative, functional microRNA-
200c gene targets in the L1- and L1Mic-435-GFP models by
combining the 681 sequence alignment predicted targets of
microRNA-200c from TargetScan with microRNA and gene
expression analysis of putative gene targets expressed in the lung
derivative oligo- or polymetastatic cell lines (L1-R2 vs L1Mic-R2)
as well as xenograft lung metastases (L1-R3 vs L1Mic-R3) (see
Methods S1). Of the 681 putative targets from TargetScan, 180
showed anti-correlation with microRNA-200c expression. Only
three of these genes were significantly and differentially expressed
between oligo and polymetastatic cell lines: FGD1 and USP25
from xenograft lung metastases and NEDD4L from lung cell lines.
We chose NEDD4 and FGD1 for validation of microRNA-200c
targeting based on their reported role in regulating EMT via TGF-
ß signaling and Rho signaling, respectively [32,33]. Shown in
Fig. 6c, NEDD4 and FGD1 each contain a putative binding site
for the microRNA-200 family members including microRNA-
200c. As expected, the expression of these two genes in
microRNA-200c mimics-treated L1-R2 cells was inhibited by
47% and 50%, respectively compared with that in control-mimics
treated cells (Fig. 6d). In contrast, the expression of vimentin, a
non-putative microRNA gene target, was not significantly altered
(Fig. 6d). These findings further strengthen the targeting
specificity of microRNA-200c and identify potential alternative
EMT-regulatory pathways in cancer cells that have lost E-
cadherin expression due to epigenetic modifications such as the
DNA methylation.
We determined the expression of the epithelial marker E-
cadherin (CDH1) and the mesenchymal marker vimentin in 5
polymetastatic and 8 oligometastatic samples (Table S1)b y
Figure 4. Validations of the prioritized human microRNAs in the animal model of oligo and polymetastases. The prioritized microRNAs
between oligometastatic and polymetastatic progression were identified in primary tumors and in metastatic tumors of clinical samples yielding two
lists: Pr-miRs and M-miRs, respectively (see Table 1a–b). These lists of microRNAs were used to rank the microRNA expression of seven cell line
samples derived from animal modeling of oligometastasis(es) (L1-R1) and of widespread polymetastases (L1Mic-R1). MicroRNA expression was
conducted in three oligometastatic L1-R2 lung cell lines as well as four polymetastatic L1Mic-R2 lung cell lines from seven distinct animals. Principal
component analysis of the expression of microRNAs was conducted in these cell line samples without providing any information on the L1-R2 or
L1Mic-R2 status. In each sample, the first component values of (a) Pr-miRs and of (b) M-miRs is sufficient to discriminate between the oligo- (L1) and
polymetastatic (L1Mic) phenotype of the animal model (Pr-miRs P=0.058; M-miRs P=0.058; two-tailed Mann-Whitney U Test, Methods S1).
doi:10.1371/journal.pone.0028650.g004
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PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28650Figure 5. microRNA-200c regulate oligo- to poly- metastasis(es) progression in the L1-R2-435-GFP xenograft model. 2610
6 control-
mimics or microRNA-200c specific mimics-treated L1-R2-435-GFP cells were tail-vein injected after 48 hr of transfection, and the development of
macrometastases was monitored (Methods). (a) microRNA-200c mimics treatment significantly converted oligometastasis(es) to largely
polymetastases. Poly: polymetastases; Oligo: oligometastasis(es). *P=0.012 (one-tailed Mann Whitney U Test). (b) Non-invasive, variable
magnification (0.14–0.896) OV-100 fluorescent imaging visualization of polymetastatic dissemination in a representative animal injected with
microRNA-200c mimics-treated L1-R2 cells. Arrows: macrometastases; green: L1-R2-435-GFP tumor; black lines in (iii): tumor blood vessels. (c) IHC
confirmation of macrometastases in the muscle (i), peritoneum membrane (ii), peritoneal cavity (iii) and lung (iv). Magnification: 1006;M :
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PLoS ONE | www.plosone.org 9 December 2011 | Volume 6 | Issue 12 | e28650immunohistochemistry. Consistent with the elevated miR-200c
expression in polymetastases and the anticipated inhibition of
EMT (Table 1), vimentin expression was detectable in 6 of the 8
oligometastatic samples and in none of the polymetastases
(P=0.016, Fischer Exact Test). CDH1 was expressed in all
polymetastatic tissue samples and in 6 of the oligometastatic tissue
samples.
Discussion
We have previously proposed oligometastases as a potentially
curable state existing between absent and widespread metastases
[1,3]. While clinical outcomes data support the existence of
oligometastasis [2,4,5,6,9], our prioritized microRNA expression is
an initial step in demonstrating a molecular basis for this phenotype
and may allow discrimination between patients with persistent
oligometastasis(es) and those who will manifest polymetastatic
progression. Our results differ from previous studies of differential
microRNA expression between non-metastatic and widely meta-
static states, or between primary and metastatic tissue within the
same subject, because our results identify characteristics of an
intermediate metastatic phenotype [34,35,36,37,38,39,40,41,42].
The oligometastatic versus polymetastatic phenotype emerges from
metastatic tissue samples as the dominant unsupervised pattern of
microRNA expression following unsupervised analysis of all
microRNAs. This pattern derives from diverse primary histologies
and metastatic sites suggesting a common molecular basis for
maintaining an oligometastatic state across a broad variety of solid
tumors.Thispattern isnotfoundinunsupervised analysisofprimary
tumors likely due to the increased genetic heterogeneity of the
primary tumor samples compared to the clonal selection present in
metastatic sites [24,35,43,44,45], though heterogeneity of cells have
alsobeenobservedovertheirprogressionattheirmetastaticsite[46].
Further, prioritized microRNAs from differential expression be-
tween oligo- and poly- metastasis(es) progression in primary samples
predicted these phenotype in metastasis(es) samples (p=0.015) of
independent patients, while microRNAs prioritized from the
metastases were less predictive in primary samples (p=0.055)
possibly due to the heterogeneity of the latter. A limitation of our
study is a relatively small human tissue sample size. However we
succeededindevelopingprioritized featuresofamicroRNAclassifier
of oligometastasis(es) for future clinical validation and testing.
Additionally, the internal consistency between several different
methods of analysis, the discrimination of oligo- and polymetastases
in the L1/-L1Mic-435-GFP animal model, as well as the ability of
microRNA-200c to convert stable oligometastasis(es) to polymeta-
static progression in L1-R2-435-GFP xenograft model, and to
enhance the lung colonization efficiency of B16F1 syngeneic model
strengthen the validity of our clinical findings. While more
investigation is necessary to identify the roles and gene targets that
separate oligometastasis(es) from widespread disease, our data
provide evidence for the molecular basis of oligometastasis(es) and
represent a first step of investigation in what is likely to be a highly
complex phenotype. Although these tumors represent different
histologic subtypes, they bear similarities in biological behavior. The
overlapping patterns of microRNAs that we have prioritized are
consistent with the fact that common biological properties (e.g.
invasion, metastasis) are shared by histologically heterogeneous
tumors during disease progression.
These results are of clinical significance because limited
metastatic disease is more common than generally recognized
[7]. For example, potentially 50% of patients with metastatic non-
small cell lung cancer, the leading cause of cancer death in men
and women, may be oligometastatic [7]. However, despite using
clinical characteristics to optimize patient selection for surgical/
radiotherapeutic intervention, only approximately 25% of oligo-
metastatic patients will experience long-term disease control with
aggressive treatment of limited metastatic disease [2,4,5]. Identi-
fication of this subset may be enhanced by using molecular
selection criteria, which could enrich the therapeutic benefit of
metastasis-directed therapy, while redirecting patients unlikely to
benefit from surgery or radiotherapy to systemic treatments.
Similarly, patients with metastatic disease that at first presentation
would appear not amenable to local treatment but exhibit an
oligometastatic genotype might benefit from a combined aggres-
sive local and systemic approach.
The direction of the prioritized microR-200c expression
changes in our clinical data sets differs from reports analyzing
expression patterns in non-metastatic versus metastatic patients.
For example, 2 of the 5 microRNAs in the microRNA-200 family
(miR-200b and miR-200c) are expressed at significantly higher
levels in metastatic tissues from oligometastatic patients who
progress to polymetastases compared to those who remain with
oligometastasis(es) (Table 1a). Our investigation of the role of
microRNA-200c in regulating oligometastatic to polymetastatic
progression in the L1-R2-435-GFP xenograft model, as well as in
regulating colonization efficiency in the B16F1 syngeneic model
has provided new biological evidence for the emerging pro-
metastasis role of microRNA200c [27] that was initially shown to
suppress metastatic dissemination [47]. The availability of our
clinically relevant animal models of oligo- and polymetastases has
advantages over other current experimental metastatic models that
were not designed to maintain a stable oligometastatic state during
consecutive rounds of in vivo selection.
Our knowledge about the role of the miR-200 family continues
to evolve. Many investigators have established that in tumorigen-
esis, one of the fundamental roles of the miR-200 family is to
maintain an epithelial phenotype (i.e., preventing epithelial-to-
mesenchymal transition) via its gene targets Zeb1 and Zeb2, the
transcriptional suppressors of E-cadherin [25,26], thus preventing
a cancer cell from initiating the process of metastasis. When
examined in the role of preventing cancer progression, investiga-
tors have shown that expression of this microRNA family can
prevent a primary tumor from initiating metastasis by maintaining
an epithelial phenotype [48]. However more recently there have
also been studies suggesting that expression of the miR-200 family
is associated with efficient metastatic colonization [27,49,50]. In
their isogenic mouse model Dykxhoorn and colleagues have
shown that after cancer cells acquire the ability to metastasize,
they cannot efficiently form metastatic lung colonies without the
expression of the miR-200 family [27]. Furthermore Elson-
Schwab et al have shown that expression of miR-200c confers a
cellular morphology that favors invasion and metastasis [50].
Finally Korpal and colleagues recently reported that miR-200s
play a critical role in promoting the latter steps of metastatic
colonization by targeting secretomes involved in metastasis
suppression. In line with these studies, our study examines the
miR-200 family in the context of a cancer cell after it has acquired
macrometastases. (d) microRNA-200c mimics treatment significantly increased the efficiency of B16F1 mouse melanoma cells to form lung
macrometastases. *P=0.0057 (one-tailed Mann Whitney U Test). (e) Representative images of mouse lung obtained from animals tail vein-injected
with microRNA-200c mimics treated (i) and control mimics treated (ii) B16F1 cells.
doi:10.1371/journal.pone.0028650.g005
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PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e28650Figure 6. microRNA-200c mimics treatment lead to specific inhibition of its putative target gene expression. L1-R2-435-GFP cells were
treated with equal amount of control-mimics or microRNA-200c mimics for 48 hours (Method). Thereafter, one fifth of the transfected cells were used
for total RNA extraction and the rest were used for tail-vein injection (Figure 5). (a) TaqMan quantification of Zeb1 and Zeb2 mRNA expression.
GPDH was used for normalization. (b) Lungs macrometastases derived from L1-R2-435-GFP cells treated with control mimics or microRNA-200c
mimics were negative for E-cadherin (i) and positive for the EMT marker vimentin (ii). (c) TargetScan alignment of microRNA-200c binding site at 39-
UTR of two computationally prioritized microRNA-200c putative targets NEDD4 and FGD1. (d) TaqMan quantification of NEDD4, FGD1 and Vimentin
mRNA expression. GPDH was used for normalization.
doi:10.1371/journal.pone.0028650.g006
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PLoS ONE | www.plosone.org 11 December 2011 | Volume 6 | Issue 12 | e28650the ability to metastasize. Our study is the first to report that
expression of miR-200c is important in the segregation of the
oligometastatic and polymetastatic states. Taken together, our
study and those of others show that phenotypes representative of
miR-200c expression vary in relation to the cellular context to
which they are examined.
Another novel set of observations derived from our xenograft
validation of microRNA-200c function is that we have identified
two new putative gene targets of microRNA-200c that may also
mediate regulation of EMT, in addition to the characterized Zeb
1/Zeb2/E-cadherin pathway. Nedd4 has been shown to inhibit
TGF-ß signal by degrading TGF-ß activated Smads and/or TGF-
ß Type 1 receptors [32,51]. Thus, down-regulation of NEDD4 by
microRNA-200c (Fig. 6e) will release its inhibition on TGF-ß
cascade allowing TGF-ß to function as a metastasis promoter
[52,53,54]. Therefore the interaction between Nedd4/TGF-ß
pathway and microRNA-200c network may represent an
alternative mechanism underlying the plasticity of an EMT state
during metastasis [55,56]. These data highlight the complexity of
microRNAs in the control of the metastatic phenotype and
represent new opportunities for future investigations.
In summary, we have identified microRNA expression features
of a potential classifier that predict the distinct outcomes of
metastatic patients who maintained stable oligometastatic disease
from those who progressed to polymetastases. We also provide
biological confirmation for molecular differences, in this case the
microRNA regulation, that underlie oligometastic to polymeta-
static progression.
Supporting Information
Figure S1 Unsupervised hierarchical clustering of pri-
mary tumors using the 344 microRNAs filtered from
TaqMan miRNA card-A (Methods). Red, black and green
represent threshold cycle values above, at or below mean level
across all samples. As expected, primary samples were clustered
according to the tissue origin and sampling site rather than their
oligo or polymetastases classifier. Abbreviations for sampling site:
Col=Colon; HNC=Head and Neck carcinoma; Ren=Renal;
Lu=Lung; Bre=Breast; Bla=Bladder; Sar=Sarcoma; Liv=
Liver; Rec=Rectum; Bow=Small bowel; Che=Chest; Ova=
Ovarian; Par=Parotid; Thy=Thymus.
(PDF)
Figure S2 Verification of the phenotypic stability of the
seven arrayed 2
nd generation cell lines via 3rd round of
animal modeling. 2610
6 purified lung derivative cell lines
established from lungs of mice described in Figure 3 and for which
the expression was determined (Fig. 4), were injected via tail-vein
of 39 NCI female athymic mice (3 oligometastatic L1 and 4
polymetastatic L1Mic cell lines). Animals developing macroscopic
observable metastases were sacrificed at the time of this finding.
The rest of the animals were sacrificed at 12-weeks post tumor cell
injection. Necropsy was performed to score macroscopic meta-
static lesions and lungs were harvested and paraffin embedded for
histological characterization. While the histology and clinical data
reported in Figure 3 refers to the cell lines extracted from lungs at
generation two and arrayed, the data reported in this Figure S3
pertain to animals injected with this second generation of cell lines
(third round of animal modeling). In mice, the polymetastases
MDA-MB-435-GFP-L1Mic cells lines produced more aggressive
metastatic progression than the oligometastases MDA-MB-435-
GFP-L1 ones in this third animal passage (odds ratio at week
12=5.6; P=0.015; one-tailed FET).
(PDF)
Figure S3 Quality of microRNA measurement in each
human samples. As a control of microRNA quality measure,
the number of detectable microRNAs per sample was plotted
using the Bioconductor package HTqPCR. Array ID 5a, 15c, and
49b are excluded from the current study because of their excessive
number of undetectable microRNAs. Further experiment by PCR
of two genes validated the RNA.
(PDF)
Figure S4 The sources of individual samples, each
representing a separate lesion is shown. The * represents
a single sample excluded because of excessive undetected
microRNAs.
(PDF)
Figure S5 Definitions of oligo- and poly- metastatic
progression.
(PDF)
Table S1 Description of patient characteristics for the
metastatic samples ordered by patient ID. Number of
metastasis(es) are listed as cumulative numbers since discovery of
primary at the time of ‘‘radiation’’ or of ‘‘tissue sampling’’. Time to
metastasis(es) is defined as time to development of metastasis(es)
after primary cancer diagnosis. Regional nodal metastasis(es) are
not included in this study and all nodal sites listed represent distant
metastases({). Metastasis(es) needed to be visible on CT or MRI at
the time of radiotherapy. The total number of metastasis(es) was
limited to #5 at the onset of the initial evaluation for treatment.
During the follow-up period, patients who remained classified with
the oligometastatic state demonstrated a cumulative number of
metastasis(es) from 1 to 5 and did not have pericardial, pleural,
cerebrospinal, or ascitic fluid. All reported count of metastasis(es)
are cumulative from time of diagnosis. Due to the continued
prospective follow-up of the patients, at any given time point the
total number of cumulative metastatic lesions per patient may
change. As an example, patient #23 underwent three resections
(one profiled) followed 15 months later by a 4th site of progression
that underwent radiotherapy. All sites of metastasis, outside of the
CNS, were treated as noted. All intracranial disease was treated
with specific doses defined by prospective cooperative group trials.
Radiosurgery (SRS) doses were at doses of 15 Gy for 3–4 cm
lesions, 18 Gy for 2–3 cm lesions, and 20 Gy for lesions ,2c mi n
maximum diameter based on Radiation Trials Oncology Group
(RTOG) 9005 criteria(i). Abbreviations: For Sample ID, leading
Ol=oligometastatic progression or not progressing, Pol=poly-
metastatic progression; HNSCC=Head and neck squamous cell
carcinoma, NSCLC=non small cell lung cancer, Met=sample of
metastatic site, #=cumulative count of.
(PDF)
Table S2 Description of patient characteristics for
primary tissue samples ordered by patient ID. The
primary tumor was treated with curative intent and controlled (i.e.,
no clinical evidence of disease) before the development of
metastatic disease in all but four patients, who each had
synchronous presentations. Number of metastasis(es) are recorded
as cumulative numbers since discovery of primary at the time of
‘‘radiation’’ or of ‘‘tissue sampling’’. Time to metastasis(es) defined
as time to development of metastasis(es) after primary cancer
diagnosis. Regional nodal metastasis(es) are not included in this
study and all nodal sites listed represent distant metastases.
Metastasis(es) needed to be visible on CT or MRI at the time of
radiotherapy. The total number of metastasis(es) was limited to #5
at the onset of the initial evaluation for treatment. During the
follow-up period, patients who remained classified with the
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metastasis(es) from 1 to 5 and did not have pericardial, pleural,
cerebrospinal, or ascitic fluid. All reported count of metastasis(es)
are cumulative from time of diagnosis. Abbreviations: HNSCC=
Head and neck squamous cell carcinoma; Ol=oligometastatic
progression or not progressing; Pol=polymetastatic progression;
Pr=sample of primary tumor, #=cumulative count of.
(PDF)
Table S3 Characteristics of patients with oligometa-
static and polymetastatic progression in metastasis(es)
samples. No patient received chemotherapy concurrently with
the radiation therapy. Adjuvant chemotherapy was initiated
following RT only for patients showed progression. Legend:
two-tailed Student t-test (t-test), two-tailed Fisher’s Exact Test
(FET), non-parametric Mann Whitney Test (MWT), logrank
survival test (Logrank), NSCLC=non small cell lung cancer,
SCLC=small cell lung cancer; a=1 brain and 1 lung metastasis
from same patient, ‘=1 omental and 1 small bowel metastasis
from same patient, *=statistically significant.
(PDF)
Table S4 Characteristics of patients with oligometa-
static and polymetastatic progression in primary tumor
samples. No patient received chemotherapy concurrently with
the radiation therapy. Adjuvant chemotherapy was initiated
following RT only for patients showed progression. Legend:
two-tailed Student t-test (t-test), two-tailed Fisher’s Exact Test
(FET), non-parametric Mann Whitney Test (MWT), logrank
survival test (Logrank), NSCLC=non small cell lung cancer,
SCLC=small cell lung cancer; a=1 brain and 1 lung metastasis
from same patient, ‘=1 omental and 1 small bowel metastasis
from same patient, *=statistically significant.
(PDF)
Table S5 Patients and treatment characteristics. No
patient received chemotherapy concurrently with the radiation
therapy. Adjuvant chemotherapy was initiated following RT only
for patients showed progression. Specifically, 20 of the 34 patients
that showed disease progression received adjuvant chemotherapy
after RT, among which 9 patients received adjuvant chemother-
apy within 6 months of radiation. The rest 14 out of the 34
patients did not receive any additional systemic therapy after RT.
(PDF)
Methods S1 Supplementary methods.
(PDF)
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